Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label VRDN-001 study for non-responders from Viridian 001-101 and 001-301
MOH_2024-08-11_013559Phase 3Not yet recruiting
- Sponsor
- Viridian Therapeutics
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of veligrotug in Graves Orbitopathy (GO), sponsored by Viridian Therapeutics. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
veligrotug
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on MOH_2024-08-11_013559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-08-11_013559.